CXF Stock Overview
A biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Chimerix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.83 |
| 52 Week High | US$1.20 |
| 52 Week Low | US$0.66 |
| Beta | 1.13 |
| 11 Month Change | 5.30% |
| 3 Month Change | -5.65% |
| 1 Year Change | -2.09% |
| 33 Year Change | -84.91% |
| 5 Year Change | -66.06% |
| Change since IPO | -94.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| CXF | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.3% | -0.2% | 0.8% |
| 1Y | -2.1% | -16.9% | 9.1% |
Return vs Industry: CXF exceeded the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: CXF underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| CXF volatility | |
|---|---|
| CXF Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CXF's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CXF's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 72 | Mike Andriole | www.chimerix.com |
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
Chimerix, Inc. Fundamentals Summary
| CXF fundamental statistics | |
|---|---|
| Market cap | €76.57m |
| Earnings (TTM) | -€79.80m |
| Revenue (TTM) | €151.78k |
504.5x
P/S Ratio-1.0x
P/E RatioIs CXF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CXF income statement (TTM) | |
|---|---|
| Revenue | US$159.00k |
| Cost of Revenue | US$73.55m |
| Gross Profit | -US$73.39m |
| Other Expenses | US$10.21m |
| Earnings | -US$83.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.93 |
| Gross Margin | -46,154.72% |
| Net Profit Margin | -52,574.84% |
| Debt/Equity Ratio | 0% |
How did CXF perform over the long term?
See historical performance and comparison